quiverquant

BioNTech and Bristol Myers Squibb Report Encouraging Phase 2 Results for Pumitamig Plus Docetaxel in Previously Treated Non-Small Cell Lung Cancer

Pumitamig plus docetaxel demonstrated a confirmed objective response rate of 36.7% in patients with non-small cell lung ...
StreetInsider.com

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

Pumitamig plus docetaxel demonstrated encouraging responses in squamous and non-squamous non-small cell lung cancer across PD-L1 expression levels with a confirmed objective response rate of ...
clinicaltrialvanguard

RELATIVITY-047’s Five-Year Data Just Made LAG-3 Biomarker Selection a Clinical Trial Design Imperative

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...